|
Galapagos Genomics
Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. History Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005. The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins. In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and G ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Naamloze Vennootschap
(; abbreviated as N.V. or NV ) or (in the French Community of Belgium) ' ('' SA'') is a type of public company defined by business law in the Netherlands, Belgium, Indonesia (where it is known as , correctly abbreviated PT and allows for private companies), and Suriname. The company is owned by shareholders, and the company's shares are not registered to certain owners, so that they may be traded on the public stock market. The phrase literally means "nameless partnership" or "anonymous venture" and comes from the fact that the partners (the shareholders) are not directly known. This is in contrast to the term for a private limited company, which is called (an "exclusive" or "closed partnership", one in which stock is not for sale on open markets). Each is a legal entity in the Netherlands, Belgium, Aruba, Curaçao, Suriname, Sint Maarten and Indonesia Indonesia, officially the Republic of Indonesia, is a country in Southeast Asia and Oceania, between the India ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Psoriasis
Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon. The five main types of psoriasis are plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases. It typically presents as red patches with white scales on top. Areas of the body most commonly affected are the back of the forearms, shins, navel area, and scalp. Guttate psoriasis has drop-shaped lesions. Pustular psoriasis presents as small, noninfectious, pus-filled blisters. Inverse psoriasis forms red patches in skin folds. Erythrodermic psoriasis occurs when the rash becomes very widespread and can develop from any of the other types. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, with Crohn's disease and ulcerative colitis (UC) being the principal types. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas UC primarily affects the colon and the rectum. Signs and symptoms In spite of Crohn's and UC being very different diseases, both may present with any of the following symptoms: abdominal pain, diarrhea, rectal bleeding, severe internal cramps/muscle spasms in the region of the pelvis and weight loss. Anemia is the most prevalent extraintestinal complication of inflammatory bowel disease (IBD). Associated complaints or diseases include arthritis, pyoderma gangrenosum, primary sclerosing cholangitis, and non-thyroidal illness syndrome (NTIS). Associations with deep vein thrombosis (DVT) and bronchiolitis obliterans organizing pneumonia (BOOP) have also been reported. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GPR84
Probable G-protein coupled receptor 84 is a protein that in humans is encoded by the ''GPR84'' gene. Discovery GPR84 (EX33) was described practically in the same time by two groups. One was the group of Timo Wittenberger in the Zentrum fur Molekulare Neurobiologie, Hamburg, Germany (Wittenberg T. et al.) and the other was the group of Gabor Jarai in Novartis Horsham Research Centre, Horsham, United Kingdom. In their papers they described the sequence and expression profile of five new members of GPC receptor family. One among them was GPR84 which represents a unique GPCR sub-family so far. Gene Hgpr84 locates to chromosome 12q13.13, and its coding sequence is not interrupted by introns. Protein The human and the murine GPR84 ORFs both encode proteins of 396 amino acid residues length with 85% identity and are therefore considered as orthologs. The hgpr84 was found by Northern blot analysis as a transcript of about 1.5 kb in brain, heart, muscle, colon, thymus, spleen, ki ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GLPG1205
GLPG1205 is an experimental drug which acts as a selective antagonist (or perhaps negative allosteric modulator) at the free fatty acid receptor GPR84. It has antiinflammatory and anti-fibrotic effects and reached Phase II human clinical trials for treatment of both ulcerative colitis and idiopathic pulmonary fibrosis, although development for both indications was ultimately dropped due to poor efficacy. However, it continues to be researched for potential applications in the treatment of other conditions such as asthma Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wh ... and acute immune-mediated liver injury. References Experimental drugs Cyclopropyl compounds Dioxanes Pyrimidoisoquinolines Ethynyl compounds Ureas {{pharm-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Janus Kinase 1
Janus kinase 1 (JAK1) is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. It interacts with the common gamma chain (γc) of type I cytokine receptors, to elicit signals from the IL-2 receptor family (e.g. IL-2R, IL-7R, IL-9R and IL-15R), the IL-4 receptor family (e.g. IL-4R and IL-13R), the gp130 receptor family (e.g. IL-6R, IL-11R, LIF-R, OSM-R, cardiotrophin-1 receptor (CT-1R), ciliary neurotrophic factor receptor (CNTF-R), neurotrophin-1 receptor (NNT-1R) and Leptin-R). It is also important for transducing a signal by type I ( IFN-α/ β) and type II ( IFN-γ) interferons, and members of the IL-10 family via type II cytokine receptors. Jak1 plays a critical role in initiating responses to multiple major cytokine receptor families. Loss of Jak1 is lethal in neonatal mice, possibly due to difficulties suckling. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Janus Kinase Inhibitor
A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes ( JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes. JAK inhibitors are used in the treatment of some cancers and inflammatory diseases such as rheumatoid arthritis and various skin conditions. A Janus kinase 3 inhibitor is attractive as a possible treatment of various autoimmune diseases since its function is mainly restricted to lymphocytes. JAK inhibitors can suppress the signaling of pro- inflammatory cytokines. Pro-inflammatory cytokines are major contributors to the cause of an over active immune system, resulting in inflammation and pain. JAK inhibitors have the ability to slow down this over activity by the suppression of the intracellular signaling. Contraindications JAK enzymes are part of the JAK/STAT pathway. This signaling ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Onno Van De Stolpe
Onno van de Stolpe (born 25 October 1959, Geldrop) is a Dutch businessman and used to be CEO of Galapagos NV, a drug discovery and development company. He retired in April 2022. Education Van de Stolpe obtained an MSc degree from the Agricultural University in Wageningen (the Netherlands). Career Van de Stolpe began his career as Manager Business Development at MOGEN in Leiden. Afterwards, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. When he returned to The Netherlands, Van de Stolpe founded Galapagos NV in 1999 when he was recruited by the CEO of Crucell to set up a new genomics division for the company. He launched the division in a joint venture with Tibotec Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Filgotinib
Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV. The most common side effects include nausea (feeling sick), upper respiratory tract infection (nose and throat infection), urinary tract infection and dizziness. Filgotinib was approved for medical use in both the European Union and Japan in September 2020. Medical uses Filgotinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease‑modifying anti‑rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). Mechanism of action Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively, similar to already marketed upadacitinib. Les ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gilead Sciences
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. Howev ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tibotec
Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment. The name of the company is derived from the ''tetrahydro-imidazo ,5,1-jk1,4]-benzodiazepine-2(1H)-one and -thione'' (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium). History In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002, and was renamed Janssen Therapeutics in June 2011. Tibotec provided funding for HIV treatment clinical trials at the I ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Crucell
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell. Janssen Vaccines is part of Johnson & Johnson Innovative Medicine business segment. __TOC__ History In 1993 Introgene, Crucell's predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell. In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs. On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
